The Effectiveness of Treatment of Giant Gastric and Duodenal Ulcers with Endonasal Electrophoresis Dalargin (Tyrosyl-D-Alanyl-Glycyl-Phenylalanyl-Leucyl-Arginine Diacetate)

Peptic ulcer disease (PUD) results from an imbalance between stomach acid-pepsin and mucosal defense barriers. It affects 4 million people worldwide annually. The incidence of PUD has been estimated at around 1.5% to 3%. Purpose of our research is to study the effect of dalargin on the course of giant gastric ulcer (GU) and duodenal ulcer (DU). Materials and Method-The study and treatment was carried out in 80 people suffering from PU, with the presence of an ulcer defect ranging in size from 2 to 7 cm in diameter. Group 1–41 people received the drug from the group of proton pump inhibitors (PPIs)-omeprazole 20 mg 2 times per day + amoxicillin 500 mg 4 times per day + metronidazole 500 mg 3 times per day-7 days, i.e. standard triple therapy. Group II, 39 people received along with standard therapy, dalargin-endonasal electrophoresis No. 12 according to the standard technique. Results-Patients with PU in both groups, who received standard therapy and standard therapy + endonasal electrophoresis of dalargin, already for 2–3 days from the moment of the start of treatment, showed significant improvement. Conclusion-It is advisable to combine standard therapy in the treatment of giant ulcers with the use of reparants, in particular, with dalargin endonasal electrophoresis